Glucose excursions in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial

Glucose excursions in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial - Glucose excursions with mitiglinide/voglibose versus glimepiride

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024817

Enrollment

Registered

2016-11-14

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

After receiving vildagliptin 100 mg, patients were randomized to have add-on therapy as either the fixed-dose combination drug mitiglinide/voglibose 10 mg/0.2 mg three times daily for a few days follo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with type 2 diabetes who were taking DPP-4 inhibitors and were admitted to the general hospital for glycemic control

Exclusion criteria

Exclusion criteria: patients with insulin dependent diabetes; known allergies to mitiglinide, voglibose, or glimepiride; hepatic dysfunction; renal dysfunction; use of corticosteroids; existing pregnancy; alcoholism; a history of severe hypoglycemic episodes; a history of diabetic ketoacidosis; diabetic retinopathy with a high risk of hemorrhage

Design outcomes

Primary

Measure	Time frame
Glycemic excursions and the frequency of hypoglycemic evaluated using CGM on the last day of both periods	—

Secondary

Measure	Time frame
Metabolic profile changes during MTT	—

Countries

Japan

Contacts

Public ContactKanta Fujimoto

Kobe City Medical Center General Hospital Internal Medicine of Diabetes and Endocrinology

kantachi@kcho.jp075-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026